Welcome to Little People of America


LPA’s Position Statement on the FDA’s Approval of Voxzogo (formerly Vosoritide) 

Little People of America (LPA), the world’s oldest and largest support organization for people with dwarfism and their families, has been tracking biotechnical developments for the treatment of individuals with Achondroplasia. With the FDA approval of Biomarin’s Voxzogo therapy, the dwarfism community has been challenged with the impact of this new treatment on our health, culture, and our standing within society.

LPA strongly believes that a focus on growth velocity is a pharmaceutical solution for the problem of society’s intolerance and indifference to people of short stature. Our community acknowledges that there are hardships associated with having dwarfism, but there are also beautiful, unique experiences not to be discounted.  We strive for our height to be reframed and seen as a part of the diverse fabric of humanity, and we wholeheartedly embrace that diversity.  We want to reprioritize research goals to be the most meaningful ones for our members, such as reducing spinal stenosis, sleep apnea, and the need for corrective surgeries, as well as supporting other improvements in quality of life.

In our mission to support people with dwarfism, LPA is working to provide accurate information to help families make these complex, emotionally charged, and life-altering choices. We believe it is our responsibility to help our members better understand their patient rights and to advocate for a research focus on healthcare outcomes beyond growth velocity.

We respect the personal choices of families or individuals regarding healthcare decisions and welcome all individuals and families to be part of LPA, regardless of medical decisions and outcomes and recognize the complexity and sensitivity of this topic for our community.

Our role is to provide social support and advocacy for its members and their community. As part of this role, LPA supports medical research, especially that which holds the potential to improve the quality of life of our members by treating symptoms that can range from uncomfortable to lethal. As medical science moves forward, we will continue to inform researchers about the value of dwarf pride and its contributions to human biological, social, and cultural diversity.

For media inquiries, please contact LPA's Public Relations Director at [email protected].

LPA's Biotech Industry Liaison Committee has established a comprehensive overview of the latest biotechnology developments in skeletal dysplasias or dwarfisms.  Click HERE to read.

Benefits of Membership

Membership is available to individuals with a medical diagnosis of dwarfism or form of short stature, as well as their families, grandparents, relatives, and all medical professionals. Benefits of membership include: peer, parent, and medical support at the chapter, regional and national level; discounted rates at the National conference; advocacy; LPA Today quarterly magazine; monthly eNewsletter, college scholarships and support; adoption and conference attendance grants; friendship and connections; referrals to medical care by dwarfism specialists; and general support for the dwarfism community.



LPA Members were asked, "What does LPA mean to you?" This word cloud was created from the responses. Words are scaled in accordance with how many times they were mentioned. The full results of our membership survey can be seen here.